<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00382447</url>
  </required_header>
  <id_info>
    <org_study_id>CCC# 26168</org_study_id>
    <nct_id>NCT00382447</nct_id>
  </id_info>
  <brief_title>Breath Actuated Nebulizer Study Protocol</brief_title>
  <official_title>Breath Actuated Nebulizer Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christiana Care Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Christiana Care Health Services</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the researchers' standard nebulizer and a breath actuated nebulizer to examine&#xD;
      if breathing medication can be delivered more quickly and as effectively or more effectively&#xD;
      than the standard nebulizer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Generic nebulizers as well as breath actuated nebulizers have been available and FDA approved&#xD;
      to administer therapy for years. Recently there has been interest in using breath actuated&#xD;
      nebulizers to stream-line patient care in the hospital setting. Literature has found that&#xD;
      breath actuated nebulizers are not only faster at delivering an equivalent dose, but more&#xD;
      effective when measuring patient response to that therapy. There is no standard for method of&#xD;
      converting from generic nebulizers to breath actuated technology.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      We want to evaluate the use of Breath Actuated Nebulizer (BAN) technology versus generic&#xD;
      nebulizers to improve quality of patient treatments and reduce nebulization duration to allow&#xD;
      staff time to do complete patient assessments.&#xD;
&#xD;
      Inclusion Criteria:&#xD;
&#xD;
        -  Adult patients with orders for routine 2.5 mg albuterol sulfate nebulizer therapy&#xD;
           ordered either Q4 or Q6 hours who consent to the study.&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        -  Adults with nebulizer therapy ordered more frequently than Q4 hours.&#xD;
&#xD;
        -  Adults with nebulizer therapy ordered less frequently than Q6 hours.&#xD;
&#xD;
        -  Pregnant patients are excluded.&#xD;
&#xD;
        -  Adults with orders for albuterol sulfate &gt; 2.5 mg.&#xD;
&#xD;
        -  Adults in the intensive care unit (ICU) or Emergency Department.&#xD;
&#xD;
      Protocol:&#xD;
&#xD;
        1. Adult patient ordered for Q4 to Q6 2.5 mg albuterol sulfate nebulizer therapy with or&#xD;
           without anticholinergic agent (ipratropium/tiotropium)&#xD;
&#xD;
        2. Patient is consented&#xD;
&#xD;
        3. Patient is randomized to receive either &quot;Control Method&quot; or &quot;Study Method&quot; first (see&#xD;
           methods below)&#xD;
&#xD;
        4. The 1st morning after consent, the first study method is used&#xD;
&#xD;
        5. The 2nd morning after consent, the other study method is used&#xD;
&#xD;
        6. Study is over after the second study method is completed&#xD;
&#xD;
      Control Method:&#xD;
&#xD;
        1. Baseline patient data with spirometry is recorded including:&#xD;
&#xD;
           Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1),Forced&#xD;
           Expiratory Ratio (FER), Peak Expiratory Flow (PEF), HR, Resting RR, Breath sounds, Pulse&#xD;
           Oximetry (SpO2).&#xD;
&#xD;
        2. 2.5 mg albuterol sulfate is given with generic nebulizer for the 0700 treatment time.&#xD;
           Anticholinergic agents such as ipratropium or tiotropium are given as ordered.&#xD;
&#xD;
        3. Follow-up patient data with spirometry is recorded at 15 minutes and 2 hours following&#xD;
           the treatment.&#xD;
&#xD;
        4. Subsequent treatments that day are given as standard.&#xD;
&#xD;
      Study Method:&#xD;
&#xD;
        1. Baseline patient data with spirometry is recorded including:&#xD;
&#xD;
           Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1),Forced&#xD;
           Expiratory Ratio (FER), Peak Expiratory Flow (PEF), Heart rate (HR), Resting respiratory&#xD;
           rate (RR), Breath sounds, Pulse Oximetry (SpO2).&#xD;
&#xD;
        2. Albuterol sulfate (2.5 mg) is given via Aero Eclipse BAN with 0.5 ml of saline or 0.5 ml&#xD;
           of ipratropium bromide (if ipratropium bromide is ordered).&#xD;
&#xD;
        3. Follow-up patient data with spirometry is recorded at 15 minutes and 2 hours following&#xD;
           the treatment.&#xD;
&#xD;
        4. Subsequent treatments that day are given as ordered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to put forth the human resources for patient enrollment&#xD;
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced vital capacity</measure>
    <time_frame>1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1</measure>
    <time_frame>1</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Asthma</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard nebulizer versus standard breath actuated nebulizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>standard nebulizer</intervention_name>
    <description>Standard small volume nebulizer for aerosolized medication delivery</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>breath actuated nebulizer</intervention_name>
    <description>Nebulizer that dispenses medication only during the inspiratory phase</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with orders for routine 2.5 mg albuterol sulfate nebulizer therapy&#xD;
             ordered either Q4 or Q6 hours who consent to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults with nebulizer therapy ordered more frequently than Q4 hours.&#xD;
&#xD;
          -  Adults with nebulizer therapy ordered less frequently than Q6 hours.&#xD;
&#xD;
          -  Pregnant patients are excluded.&#xD;
&#xD;
          -  Adults with orders for albuterol sulfate &gt; 2.5 mg.&#xD;
&#xD;
          -  Adults in the ICU or Emergency Department.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John S. Emberger, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christiana Care Health Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>September 27, 2006</study_first_submitted>
  <study_first_submitted_qc>September 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2006</study_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breath actuated nebulizer</keyword>
  <keyword>nebulizer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

